Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project)

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 6, 2010, Pages 686-690

  Roobol, M J ^a   Bangma, C H ^a   el Bouazzaoui, S ^a   Franken Raab, Conja G ^a   Zwarthoff, Ellen C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Bladder cancer; Early detection; FGFR3; Hematuria; Methylation tests; Micro satellite analyses; Molecular tests; NMP22; Population based

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2; NUCLEAR MATRIX PROTEIN 22;

ADULT; AGED; BLADDER CANCER; CANCER SCREENING; CYSTOSCOPY; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRIORITY JOURNAL; REVIEW;

AGED; DNA METHYLATION; EARLY DETECTION OF CANCER; FEASIBILITY STUDIES; HEMATURIA; HUMANS; MALE; MASS SCREENING; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 78149395455     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.12.002     Document Type: Review

References (29)

1. Parkin D.M. The global burden of urinary bladder cancer. Scand J Urol Nephrol 2008, 218(Suppl.):12-20. Review.
2. Hemelt M., Yamamoto H., Cheng K.K., et al. The effect of smoking on the male excess of bladder cancer: A meta-analysis and geographical analyses. Int J Cancer 2008, 2:412-419.
3. Jankovic S., Radosavljevic V. Risk factors for bladder cancer. Tumori 2007, 1:4-12.
4. Zeegers M.P., Swaen G.M., Kant I., et al. Occupational risk factors for male bladder cancer: Results from a population-based case cohort study in The Netherlands. Occup Environ Med 2001, 58:590-596.
5. Droller M.J. Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. J Urol 2001, 165:696-697.
6. Heney N.M. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 1992, 19:429-433.
7. Britton J.P., Dowell A.C., Whelan P. Dipstick hematuria and bladder cancer in men over 60: Results of a community study. BMJ 1989, 299:1010-1012.
8. Britton J.P., Dowell A.C., Whelan P., et al. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 1992, 148:788-790.
9. Messing E.M., Young T.B., Hunt V.B., et al. Home screening for hematuria: Results of a multiclinic study. J Urol 1992, 148:289-292.
10. Messing E.M., Young T.B., Hunt V.B., et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening vs. those with standard clinical presentations. Urology 1995, 45:387-396.
11. Messing EM. Urothelial tumors of the urinary tract. Campbell's Urology, 8th edition, Vol IV, [chapter 76]. Philadelphia, PA: Saunders. p. 2732-84.
12. Van Rhijn B.W.G. Molecular diagnosis and prognosis of bladder cancer. Towards the implementation of molecular markers in clinical practice. Thesis, Erasmus Medical Center 2005.
13. van der Aa M.N., Zwarthoff E.C., Steyerberg E.W., et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: Feasibility and clinical utility in a prospective multicenter study. Eur Urol 2009, 55:659-667. (Cost-Effectiveness of Follow-Up of Urinary Bladder [CEFUB] cancer trial).
14. Grossman H.B., Messing E., Soloway M., et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005, 291:810-816.
15. Glas A.S., Roos D., Deutekom M., et al. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003, 169:1975-1982.
16. Steiner G., Schoenberg M.P., Linn J.F., et al. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 1997, 3:621-624.
17. Van Rhijn B.W.G., van der Poel H.G., van der Kwast T.H. Urine markers for bladder cancer surveillance. A systematic review. Eur Urol 2005, 47:736-748.
18. Simon M.A., Lokeshwar V.B., Soloway M.S. Current bladder cancer tests: Unnecessary or beneficial?. Crit Rev Oncol Hematol 2003, 47:91-107.
19. Cappellen D., De Oliveira C., Ricol D., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999, 23:18-20.
20. van Rhijn B.W.G., Vis A.N., van der Kwast T.H., et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1is superior to pathological grade for the prediction of clinical outcome. J Clin Oncol 2003, 21:1912-1921.
21. Rieger-Christ K.M., Mourtzinos A., Lee P.J., et al. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 2003, 98:737-744.
22. van Rhijn B.W., Lurkin I., Chopin D.K., et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res 2003, 9:257-263.
23. van Oers J.M., Lurkin I., van Exsel A.J., et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005, 11:7743-7748.
24. Dulaimi E., Uzzo R.G., Greenberg R.E., et al. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004, 10:1887-1893.
25. Friedrich M.G., Weisenberger D.J., Cheng J.C., et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004, 10:7457-7465.
26. Hoque M.O., Begum S., Topaloglu O., et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006, 98:996-1004.
27. Chan M.W., Chan L.W., Tang N.L., et al. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 2003, 104:611-616.
28. Malkowicz S.B. Management of Superficial Bladder Cancer. Campbell's Urology 2002, IV:2785. Saunders, Philadelphia, PA. 8th ed. P.C. Walsh, E.D. Vaughn, A.J. Wein (Eds.).
29. Botteman M.F., Pashos C.L., Redaelli A., et al. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 2003, 21:1315-1330.